XM does not provide services to residents of the United States of America.

Financials and IT weigh on Indian shares



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Financials and IT weigh on Indian shares</title></head><body>

Updates at 10:45 a.m. IST

By Kashish Tandon

Dec 19 (Reuters) -Indian shares inched loweron Friday, weighed down by ITand financials, as investors remained jittery aboutthe Federal Reserve's projection of fewer rate cuts next year, which has spurred anexodus of foreign funds.

The Nifty 50 .NSEI was down 0.1%at 23,928.60 asof 10:45 a.m. IST, while the BSE Sensex .BSESN shed 0.2%to 79,078.69.

Both benchmarks have logged weekly losses of over3% so far. The indexes are heading for their first weekly decline in five.

The Fed this week delivereda quarter-pointrate cut but forecast two reductions in 2025, half of what policymakers had anticipated, dampeningforeign investors' appetite for Indian equities.

They offloaded 122.31 billion rupees ($1.44 billion)of stocks this week untilThursday, but are still net buyers in December after being net sellers for two straight months.

U.S. rate cuts tend to help emerging markets assets, such as Indian equities, as they boost foreign inflows.

In Mumbai, heavyweightfinancials .NIFTYFIN dropped 0.3%,with Axis Bank AXBK.NS sliding 2.2%.

Domestic IT firms .NIFTYIT, which earn a chunk of their revenue from the U.S. and are sensitive to the country'sinterest rates, fell 0.2%,giving up early gains after peer AccentureACN.N beat quarterly revenue and profit estimates.

"Even though Accenture's upbeat results gave an initial boost to tech stocks, Fed's hawkish rate cut outlook has hurt sentiment and foreign investment inflows are still negative," said Anita Gandhi, founder and head of institution at Arihant Capital Markets.

Meanwhile, pharma stocks .NIPHARM, which earn most of their revenue from exports, climbed 0.3% andwere set for a weekly gain of 3%.

The Indian rupee INR=IN hit an all-time low of 85.10 on Friday onpersistent dollar strength, making it cheaper for other countries to import drugs from India.

Among individual stocks, battery maker Amara Raja AMAR.NS gained as much as 5% after Hyundai Motor India HYUN.NS said it would equip its domestic cars with the company's absorbent glass mat battery technology.



($1 = 85.0860 Indian rupees)



Reporting by Kashish Tandon in Bengaluru; Editing by Eileen Soreng and Sonia Cheema

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.